CD19 and diffuse large B-cell lymphoma: The umbrella review assessing relapsed/refractory DLBCL revealed no statistically significant enhancement in CR rates among patients receiving CD28/CD19/CD20 CAR-T therapy (OR: 1.09, 95% CI: 0.79–1.51), 41BB/CD19/CD20 CAR-T therapy (OR: 0.71, 95% CI: 0.48–1.04), CD20 CAR-T monotherapy (OR: 0.95, 95% CI: 0.74–1.21), or CD19 CAR-T monotherapy (OR: 0.97, 95% CI: 0.75–1.25) when compared to placebo; all findings were derived from moderate-quality evidence (Figures 2, 3) (11).